UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 178

Sortiert nach

Joint Disease Activity in Inflammatory Bowel Disease–associated Peripheral Spondyloarthritis Stratifies Therapeutic Response

Gastro hep advances, 2022, Vol.1 (2), p.137-140

2022

Volltextzugriff (PDF)

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S001-S002

2021

Volltextzugriff (PDF)

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2015-06, Vol.41 (12), p.1303-1304

2015

Volltextzugriff (PDF)

Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy

Clinical gastroenterology and hepatology, 2022-04, Vol.20 (4), p.962-963

2022

Volltextzugriff (PDF)

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2008-10, Vol.135 (4), p.1130-1141

2008

Volltextzugriff (PDF)

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

The Journal of experimental medicine, 2014-07, Vol.211 (8), p.1571-1583

2014

Volltextzugriff (PDF)

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

The New England journal of medicine, 2012-10, Vol.367 (16), p.1519-1528

2012

Volltextzugriff (PDF)

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Gastroenterology (New York, N.Y. 1943), 2016-06, Vol.150 (7), p.1568-1578

2016

Volltextzugriff (PDF)

P382 Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn’s Disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i517-i517

2023

Volltextzugriff (PDF)

A Population-Based Survey of the Social and Personal Impact of Headache

Headache, 1994-06, Vol.34 (6), p.344-350

1994

Volltextzugriff (PDF)

P245 The Relationship Between the Endoscopic Healing Index and Magnetic Resonance Enterography In Crohn’s Disease Patients

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i396-i397

2023

Volltextzugriff (PDF)

P912 Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i1025-i1025

2023

Volltextzugriff (PDF)

P704 Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE Registry

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1329-i1329

2024

Volltextzugriff (PDF)

DOP35 Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i135-i136

2024

Volltextzugriff (PDF)

DOP76 No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S109-S110

2021

Volltextzugriff (PDF)

P065 Metabolic utilisation of propanediol by adherent-invasive E. coli regulates intestinal tissue immunity

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S166-S167

2020

Volltextzugriff (PDF)

OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i19-i20

2023

Volltextzugriff (PDF)

The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients

The American journal of gastroenterology, 2004-04, Vol.99 (4), p.656-661

2004

Volltextzugriff (PDF)

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i379-i380

2022

Volltextzugriff (PDF)

DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S117-S118

2021

Volltextzugriff (PDF)

P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S488-S489

2021

Volltextzugriff (PDF)

DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S113-S115

2021

Volltextzugriff (PDF)

OP40 A core transferable microbiota in responders to faecal microbiota transplant for ulcerative colitis shape mucosal T-cell immunity

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S040-S041

2020

Volltextzugriff (PDF)

Takotsubo cardiomyopathy after an upper and lower endoscopy: a case report and review of the literature

Journal of medical case reports, 2019-03, Vol.13 (1), p.81-81, Article 81

2019

Volltextzugriff (PDF)

Comparison of Dihydroergotamine With Metoclopramide Versus Meperidine With Promethazine in the Treatment of Acute Migraine

Headache, 1995-05, Vol.35 (5), p.256-259

1995

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(142)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(177)
Japanisch
(17)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Joint Disease Activity in Inflammatory Bowel Disease–associated Peripheral Spondyloarthritis Stratifies Therapeutic Response

OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study

Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease

Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

P382 Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn’s Disease

A Population-Based Survey of the Social and Personal Impact of Headache

P245 The Relationship Between the Endoscopic Healing Index and Magnetic Resonance Enterography In Crohn’s Disease Patients

P912 Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease

P704 Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: The SAPPHIRE Registry

DOP35 Spatial transcriptomics reveals cellular niches associated with histological inflammation in postoperative Crohn’s Disease

DOP76 No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD

P065 Metabolic utilisation of propanediol by adherent-invasive E. coli regulates intestinal tissue immunity

OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension

The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients

P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

DOP86 Corticosteroid-sparing effects of ustekinumab therapy for Ulcerative Colitis through 3 years: UNIFI long-term extension

P508 Dose adjustment in patients with moderate to severe ulcerative colitis: results from year 3 of the UNIFI maintenance study long-term extension

DOP83 Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

OP40 A core transferable microbiota in responders to faecal microbiota transplant for ulcerative colitis shape mucosal T-cell immunity

Takotsubo cardiomyopathy after an upper and lower endoscopy: a case report and review of the literature

Comparison of Dihydroergotamine With Metoclopramide Versus Meperidine With Promethazine in the Treatment of Acute Migraine

Suchergebnisse filtern